Orion's collaborator, MSD, expands clinical development program for opevesostat to women's cancers
ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST
Orion's collaborator, MSD, expands clinical development program for opevesostat to women's cancers
Orion's collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women's cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of opevesostat for the treatment of breast, endometrial and ovarian cancers has been posted to ClinicalTrials.gov database. The study is not yet recruiting patients.
Further information is available on ClinicalTrials.gov:
A Study of MK-5684 in People With Certain Solid Tumors (study identifier: NCT06979596)
MSD has global exclusive rights to opevesostat which is an oral, non-steroidal and selective inhibitor of CYP11A1 discovered and developed by Orion. MSD is currently evaluating opevesostat in several clinical trials, including two Phase 3 trials, for the treatment of metastatic castration-resistant prostate cancer.
Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orionpharma.com
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Tesla Delivery Estimates Cut at Oppenheimer Amid Key Market Weakness, Expected Removal of EV Credits
Tesla's (TSLA) deliveries in 2025 and 2026 will likely take a hit amid weakness in China and the Eur
Business Upturn
2 days ago
- Business Upturn
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
By GlobeNewswire Published on June 6, 2025, 23:41 IST Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) — First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 days ago
- Yahoo
Spotify Technology (NYSE:SPOT) Reports Sales Growth to €4.2 Billion
Spotify Technology saw its share price rise by nearly 34% over the last quarter. The major catalyst was the company's announcement of strong first-quarter earnings, reporting sales growth to EUR 4.19 billion and an increase in net income and earnings per share. This positive financial performance reinforced investor sentiment amidst robust market conditions, where major indices such as the S&P 500 have also posted gains. Spotify's confirmed revenue guidance for the upcoming quarter aligned well with overall market optimism, further supporting its share price growth, while its stagnant buyback activity had little effect on counterbalancing these upward movements. Buy, Hold or Sell Spotify Technology? View our complete analysis and fair value estimate and you decide. We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent announcement of Spotify Technology's strong first-quarter earnings, reflecting sales growth to €4.19 billion, has reinforced its positive growth narrative. This signals potential revenue expansion as subscription growth in markets like Latin America and Asia Pacific continues. The company's focus on enhancing user engagement through AI, new monetization systems, and scaling product features could further bolster its earnings potential amid current market optimism. Over the longer term, Spotify's total shareholder return reached a very large value of 536.84% over three years, reflecting steady growth and investor confidence. When comparing its performance to the broader market or the entertainment industry over the last year, Spotify's one-year return exceeded the US Entertainment industry's return of 62% and surpassed the US Market's 11% return. This underscores its strength in navigating challenging market conditions. The positive market sentiment and strong financial performance could influence revenue and earnings forecasts. Analysts project substantial annual earnings growth of 25.4% over the next three years. The share price increase, in context to the consensus price target of US$666.48, suggests room for potential growth given the current share price of US$576.94 being 13.4% below the target. However, variance in analyst projections indicates varying expectations, emphasizing the importance of personal analysis aligned with individual expectations. Examine Spotify Technology's earnings growth report to understand how analysts expect it to perform. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:SPOT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
